Pluri (PLUR)

Pluri’s therapeutic pipeline is built around placenta-derived cell candidates, including PLX-PAD and PLX-R18. These programmes are being evaluated for conditions linked to inflammation, muscle injury, blood-cell recovery, and other medical needs where cell-based approaches may offer a different mechanism from conventional drugs. The company’s platform allows cells to be expanded without relying on traditional two-dimensional culture methods, which can be a limiting factor in cell therapy manufacturing.

Beyond its internal drug-development programmes, Pluri also operates in contract development and manufacturing through PluriCDMO. This business uses the company’s process knowledge and manufacturing infrastructure to support third parties working on cell-based products. In addition, Pluri applies its cell expansion capabilities to non-medical markets, including cultivated food products such as cell-cultured coffee and meat, as well as agricultural applications.

As a listed biotechnology company, PLUR is exposed to the long development timelines, regulatory requirements, and financing needs typical of advanced therapy businesses. Its distinguishing feature is the breadth of its platform: Pluri is not focused solely on a single drug candidate, but on using scalable cell production technology across several industries where biological manufacturing is becoming increasingly important.